Chimeric Therapeutics (Australia) Analysis
| CHM Stock | 0.01 0 16.67% |
Chimeric Therapeutics is fairly valued with Real Value of 0.004864 and Hype Value of 0.006163. The main objective of Chimeric Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Chimeric Therapeutics is worth, separate from its market price. There are two main types of Chimeric Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Chimeric Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Chimeric Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Chimeric Therapeutics stock is traded in Australia on Australian Securities Exchange, with the market opening at 09:50:00 and closing at 16:12:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Australia. Chimeric Therapeutics is usually not traded on Australia Day, Australia Day ( substitute day ), Good Friday, Easter Monday, ANZAC Day, Christmas Day, Boxing Day, New Year 's Day. Chimeric Stock trading window is adjusted to Australia/Sydney timezone.
Chimeric |
Chimeric Stock Analysis Notes
About 19.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.7. Some equities with similar Price to Book (P/B) outperform the market in the long run. Chimeric Therapeutics recorded a loss per share of 0.02. The entity had not issued any dividends in recent years. For more info on Chimeric Therapeutics please contact Jennifer Chow at 61 3 9824 5254 or go to https://www.chimerictherapeutics.com.Chimeric Therapeutics Investment Alerts
| Chimeric Therapeutics is way too risky over 90 days horizon | |
| Chimeric Therapeutics has some characteristics of a very speculative penny stock | |
| Chimeric Therapeutics appears to be risky and price may revert if volatility continues | |
| Chimeric Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 7.46 M. Net Loss for the year was (12.53 M) with profit before overhead, payroll, taxes, and interest of 2.04 M. | |
| Chimeric Therapeutics generates negative cash flow from operations | |
| About 19.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Chimeric Therapeutics Appoints New Director, Miles Prince - TipRanks |
Chimeric Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.08 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Chimeric Therapeutics's market, we take the total number of its shares issued and multiply it by Chimeric Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Management Efficiency
Chimeric Therapeutics has return on total asset (ROA) of (0.4871) % which means that it has lost $0.4871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.8009) %, meaning that it generated substantial loss on money invested by shareholders. Chimeric Therapeutics' management efficiency ratios could be used to measure how well Chimeric Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Chimeric Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 5.7 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 9.1 M in 2025.Leadership effectiveness at Chimeric Therapeutics is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Technical Drivers
As of the 21st of July, Chimeric Therapeutics shows the Mean Deviation of 8.2, risk adjusted performance of 0.0912, and Downside Deviation of 17.26. Chimeric Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Chimeric Therapeutics Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Simple Moving Average indicator is calculated by adding the closing price of Chimeric Therapeutics for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Chimeric Therapeutics short-term fluctuations and highlight longer-term trends or cycles.
Chimeric Therapeutics Outstanding Bonds
Chimeric Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Chimeric Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Chimeric bonds can be classified according to their maturity, which is the date when Chimeric Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Chimeric Therapeutics Predictive Daily Indicators
Chimeric Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Chimeric Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Chimeric Therapeutics Forecast Models
Chimeric Therapeutics' time-series forecasting models are one of many Chimeric Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Chimeric Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Chimeric Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Chimeric Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Chimeric shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Chimeric Therapeutics. By using and applying Chimeric Stock analysis, traders can create a robust methodology for identifying Chimeric entry and exit points for their positions.
Chimeric Therapeutics is entity of Australia. It is traded as Stock on AU exchange.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Chimeric Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Crypto Correlations Now
Crypto CorrelationsUse cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
| All Next | Launch Module |
Additional Tools for Chimeric Stock Analysis
When running Chimeric Therapeutics' price analysis, check to measure Chimeric Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chimeric Therapeutics is operating at the current time. Most of Chimeric Therapeutics' value examination focuses on studying past and present price action to predict the probability of Chimeric Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chimeric Therapeutics' price. Additionally, you may evaluate how the addition of Chimeric Therapeutics to your portfolios can decrease your overall portfolio volatility.